Context for Intuitive Surgical’s recent share performance

Intuitive Surgical (ISRG) has drawn renewed attention after a period where the stock is roughly flat over the past month and shows a negative move over the past 3 months, prompting investors to reassess its fundamentals.

With a market value near US$160b and annual revenue of US$10.58b, the company sits at scale in robotic and minimally invasive medical equipment, giving investors plenty of hard numbers to weigh against recent share price moves.

The recent 19.3% year to date share price decline sits alongside a 65.79% total shareholder return over five years, suggesting longer term holders have still seen meaningful gains even as shorter term momentum has faded.

If Intuitive Surgical’s mixed momentum has you reassessing your watchlist, this is a good moment to size up other opportunities in medical technology and review 32 robotics and automation stocks

So with the stock down 19.3% year to date, yet backed by US$10.58b in annual revenue and US$2.98b in net income, is Intuitive Surgical quietly offering value, or is the market already pricing in everything ahead?

Most Popular Narrative: 14.8% Undervalued

According to the most followed narrative on Intuitive Surgical, the fair value sits at $532.46 compared with the last close at $453.49. This frames the recent share pullback in a different light.

A Growing Installed Base is good but the Recurring Revenue makes the Difference

Today, 9,539 da Vinci systems are installed worldwide, with an annual growth rate of 15.1%. Each year, these systems perform approximately 2.2 million procedures, a number that has been growing at a rate of 22.2% per year.

This high number of procedures ensures a strong demand for replacement parts and services, which now account for 83% of Intuitive’s total revenue. This share has increased from 79% in the previous year, highlighting how the company’s business model has evolved into a high-margin, subscription-like revenue stream.

Want to see how recurring procedures, margin assumptions, and future profit multiples combine into that fair value call? The full narrative lays out the numbers behind those expectations in plain sight.

According to Tokyo, the narrative rests on specific views about future revenue growth, profitability, and the type of earnings multiple Intuitive Surgical could sustain, all filtered through a discount rate of 6.77% to reach a fair value estimate of $532.46.

Result: Fair Value of $532.46 (UNDERVALUED)

However, this fair value story still competes with risks such as slower than expected procedure growth or hospitals delaying new da Vinci system purchases.

Another take: multiples paint a richer pricing picture

While Tokyo’s narrative pegs fair value at $532.46, current pricing also needs to be weighed against what investors pay for each dollar of earnings. Intuitive Surgical trades on a P/E of 53.9x versus 24.1x for the US Medical Equipment industry and 25.8x for peers, while the fair ratio sits at 32.1x. This points to a stock that the market already prices richly and leaves less room for error if growth expectations soften.

Next Steps

If this mix of optimism and caution has you unsure, consider acting while sentiment is still taking shape and weigh the potential yourself by checking the 3 key rewards

Looking for more investment ideas?

If Intuitive Surgical is already on your radar, do not stop there. Widen your search now so you are not relying on a single opportunity.

• Target potential mispricings by scanning 51 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect those traits.
• Prioritise resilience by checking 72 resilient stocks with low risk scores where companies pair steadier risk profiles with business models focused on durability.
• Hunt for future standouts by reviewing the screener containing 23 high quality undiscovered gems before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.